Common Deficiencies with Bioequivalence Submissions in Abbreviated New Drug Applications Assessed by FDA

Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 1

Abstract

A generic product must meet the standards established by the Food and Drug Administration (FDA) to be approved for marketing in the USA. FDA approves a generic product for marketing if it is proved to be therapeutically equivalent to the reference product. Bioequivalence (BE) between a proposed generic product and its corresponding reference product is one of the major components of therapeutic equivalence. These approvals may be delayed if the BE portion of the submission is determined to be deficient. Many of these BE deficiencies recur commonly and can be avoided.

Authors and Affiliations

Qing Liu, Barbara M. Davit, Svetlana A. Cherstniakova, Suman Dandamudi, Johnetta F. Walters, Christina H. Lee, Kimberly W. Raines, Ke Ren, Leeh N. Williamson, Dale P. Conner

Keywords

Related Articles

Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson’s disease

Parkinson’s disease (PD) is a debilitating movement disorder resulting from a progressive degeneration of the nigrostriatal dopaminergic pathway and depletion of neurotransmitter dopamine in the striatum. Molecul...

Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rats

VNP40101M (1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(2 methylamino)carbonyl] hydrazine), a novel DNA alkylating agent, is currently under clinical development for the treatment of cancer in Phase I clinical trials. T...

Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats

Biochanin A(BCA) is a dietary isoflavone present in legumes, most notably red clover, and in many herbal dietary supplements. BCA has been reported to have chemopreventive properties and is metabolized to the isoflavone...

Procedural elements involved in maintaining bioanalytical data integrity for good laboratory practices studies and regulated clinical studies

This article describes procedural elements involved in ensuring the integrity of bioanalytical data. These elements can be divided into 3 areas. First, there are those ensuring the integrity of the analyte until analysis...

Download PDF file
  • EP ID EP681195
  • DOI  10.1208/s12248-011-9312-7
  • Views 75
  • Downloads 0

How To Cite

Qing Liu, Barbara M. Davit, Svetlana A. Cherstniakova, Suman Dandamudi, Johnetta F. Walters, Christina H. Lee, Kimberly W. Raines, Ke Ren, Leeh N. Williamson, Dale P. Conner (2012). Common Deficiencies with Bioequivalence Submissions in Abbreviated New Drug Applications Assessed by FDA. The AAPS Journal, 14(1), -. https://europub.co.uk/articles/-A-681195